- An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adultsKarin Levie
Ecole de Santé Publique, Universite Catholique de Louvain, Brussels
J Infect Dis 198:642-9. 2008..To protect a naive global population against pandemic influenza, pandemic vaccines should be effective at low antigen doses, because of limited manufacturing capacity...
- Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescentsDominique Boutriau
GlaxoSmithKline Biologicals, Rue de l Institut 89, 1330 Rixensart, Belgium
Clin Vaccine Immunol 14:65-73. 2007....
- Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trialLeon Heron
National Center for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Childrens Hospital, Westmead, Australia
Vaccine 25:2817-22. 2007..Both regimens were shown to be safe and well tolerated. Two doses of Engerix-B (20 microg HBsAg) could be considered as an alternative to standard three-dose Engerix-B (10 microg HBsAg) immunisation for adolescents aged 11-15 years...